Phase 2 Peripheral Neuropathy Trial, Recruiting NCT07036796 Sponsor: Ain Shams University Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT07036796
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 40 and 75 years old who have been diagnosed with type 2 diabetes
  • People who have had diabetes for at least 1 year
  • People who have been diagnosed with diabetic peripheral neuropathy (nerve damage in the hands or feet related to diabetes)
  • People whose diabetes medications have stayed the same for at least 1 month before joining and who are expected to keep the same medications throughout the trial

Who may not be able to join:

  • People who have an autoimmune condition (such as lupus or rheumatoid arthritis), a thyroid condition, a disease affecting blood flow in the limbs, or any type of cancer
  • People who have serious kidney or liver problems
  • People who have been diagnosed with a condition that causes progressive loss of nerve or brain function (such as Parkinson's disease or Alzheimer's disease)
  • People who currently have an active infection
  • People who take any medications or supplements known to cause or help treat nerve damage in the limbs
  • People who drink alcohol heavily or use substances (confirm with trial site for specific thresholds)
  • People who have taken antioxidant supplements or anti-inflammatory medicines within the 3 months before joining, or who plan to take them during the trial
  • People who are pregnant, breastfeeding, or planning to become pregnant during the study
  • People who have a known allergy to melatonin

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 July 2025
Est. completion
4 July 2027

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Concentration of human nuclear factor erythroid 2-related factor (Nrf2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov